Skip to content

Clinical study of frozen-thaw embryo transplantation using hydroxychloroquine and gonadotropin-releasing hormone agonists in recurrent reproductive failure or repeated implantation failure patients with undifferentiated connective tissue disease

A prospective cohort study of frozen-thaw embryo transplantation using hydroxychloroquine and gonadotropin-releasing hormone agonists in recurrent reproductive failure or repeated implantation failure patients with undifferentiated connective tissue disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056921
Enrollment
Unknown
Registered
2022-02-22
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent reproductive failure patients with undifferentiated connective disease

Interventions

FET group:None
GnRha+FET group:GnRha

Sponsors

Nanjing Maternity and Child Health Care Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.women at reproductive age (20–40 years old); 2.trying to conceive and plan to receive FET in our center(at least one high-quality cryopreservation embryo available; (3)diagnosed with RPL or RIF; (4)diagnosed with UCTD; (5)signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Any known cause of previous pregnancy loss: 1) The diagnosis was antiphospholipid antibody syndrome or other definite CTD disease; 2) Known paternal and maternal chromosome abnormalities; 3) Maternal severe endocrine dysfunction: luteal insufficiency, polycystic ovary syndrome, premature ovarian failure (follicle stimulating hormone, FSH = follicular phase 20U/L), hyperprolactinemia, thyroid diseases, diabetes and other hypothalamus pituitary adrenal axis abnormalities; 4) Female anatomical abnormalities: uterine malformation (using Thessaloniki ESHRE/ESGE consensus standard, gynecological examination, ultrasound results, and opinions of obstetricians and gynecologists), Asherman syndrome, cervical incompetence. 2. Any known serious heart, liver, kidney and blood disease: 1) ALT or AST is greater than 2 times the upper limit of normal value; 2) Creatinine clearance rate is less than 30mL/min; 3) White blood cells less than 2.5 × 109/L, hemoglobin lower than 85 g/L, or platelet lower than 50 × 109/L 3. Other acute infections: 1) Active viral hepatitis includes hepatitis B virus (HBV) and hepatitis C virus (HCV); 2) Active infections include varicella zoster virus (VZV), human immunodeficiency virus (HIV), syphilis or tuberculosis; 3) Previous history of peptic ulcer or upper gastrointestinal bleeding, malignant tumor, epilepsy or psychosis.

Design outcomes

Primary

MeasureTime frame
live birth rate per transferred cycle;

Secondary

MeasureTime frame
cumulative live birth rate;clinical pregnancy rate;biochemical pregnancy rate;continuous pregnancy rate;pregnancy loss rate;

Countries

China

Contacts

Public ContactRong Shen

Nanjing Maternity and Child Health Care Hospital

rongshen163@163.com+86 13952033229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026